Key Takeaways:
The Schall Law Firm announced an investigation into Entrada Therapeutics Inc. (NASDAQ: TRDA) after the company’s stock fell 57.3% on May 7.
"The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors," the Schall Law Firm said in a statement.
The market sell-off followed Entrada’s announcement of topline data from its ELEVATE-44-201 clinical study for a Duchenne treatment. Investors found the results underwhelming despite the company's positive characterization of the data.
The investigation could lead to a class-action lawsuit, adding significant legal and financial risk for Entrada as it struggles to regain investor confidence in its lead drug candidate.
The core of the issue lies in the clinical data for Entrada's Duchenne muscular dystrophy drug. While the company described the results from Cohort 1 of the Phase 1/2 study as “positive,” the data revealed only a slight increase in the production of a critical muscle-protecting protein. This level of improvement was perceived by the market as insufficient for the drug to be competitive against existing and developing treatments, triggering the massive stock decline.
The Schall Law Firm, a national shareholder rights litigation firm, is now soliciting investors who suffered a loss to participate in its investigation. The firm has encouraged shareholders to discuss their rights free of charge.
The decline puts the stock at its lowest since the data release, testing new lows. Entrada's next catalyst will be its response to these allegations and any subsequent legal filings.
This article is for informational purposes only and does not constitute investment advice.
